Equillium, Inc., a clinical-stage biotech firm, has reported positive primary results from the Phase 1b EQUALISE study's Type B segment, which assessed the efficacy of itolizumab in lupus nephritis patients.

The pharmaceutical industry is experiencing a surge in the sales of injectable GLP-1 drugs for weight loss, with Eli Lilly's Zepbound recently surpassing Novo Nordisk's Wegovy in new U.S. prescriptions.

The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab)

FG-3246 has shown promising results in treating adenocarcinoma within a heavily pre-treated patient group.

Kiromic BioPharma, Inc. has announced early indications of tumor stabilization in a patient enrolled in the Deltacel-01 Phase 1 clinical trial.

NANOBIOTIX has completed the dose escalation phase of a Phase 1 study evaluating NBTXR3, a potential first-in-class radioenhancer.

Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002)

A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects.

In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.

Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.

Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.

Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma